Scientific Program Committee

CROI 2008 Session 32
e Tuesday, 4-6:15 pm; Ballroom A
CME
Session 31–Oral Abstracts
HIV Molecular Biology and Host Cell Interactions
Moderators:
Alan Engelman, Dana-Farber Cancer Inst, Boston, MA, US
Dana Gabuzda, Dana-Farber Cancer Inst, Boston, MA, US
4:00 97 Early Interactions of Fluorescently Labeled HIV with
the Female Genital Tract
Scott McCoombe* 1 , A Trull1 , M McRaven1 , N Byers1 ,
M Anderson1 , J Kowalski1 , M Dinh1 , R Veazey2 , and T Hope1 1 2 Northwestern Univ, Chicago, IL, US and Tulane Natl Primate Res
Ctr, Covington, LA, US
4:15 98 Identification of LEDGF/p75 PWWP Domain Amino
Acids Residues Critical for Chromatin Binding and
HIV-1 Infection
Michelle Shun*, F Di Nunzio, and A Engelman
Dana-Farber Cancer Inst, Boston, MA, US
4:30 99 Host-specific Adaptation of the HIV-1/SIVcpz Gag
Matrix Protein
Frederic Bibollet-Ruche* 1 , J Decker1 , J Easlick1 , B Keele1 , Y Li1 ,
J Takehisa1 , M Krauss1 , G Shaw1 , P Sharp2 , and B Hahn1 1 2 Univ of Alabama at Birmingham, US and Univ of Edinburgh, UK
4:45 100 Vpr Binds to DCAF1 and to DDB1 to Mediate Its
Biological Functions in a Species-specific Interaction
Yoshiyuki Hakata* and N Landau
New York Univ Sch of Med, New York, US
5:00 101 The Role of Human Staufen in the Intracellular
Trafficking of Unspliced HIV-1 RNA
Nan Yan* and J Lieberman
Immune Disease Inst, Boston, MA, US and Harvard Med Sch,
Boston, MA, US
5:15 102 Identification of a Novel ESCRT-I Subunit and Other
ESCRT-I Binding Factors Required for Efficient HIV-1
Release
Virginie Sandrin* 1 , E Morita1 , MA Karren1 , S Gygi2 , S Morham3 ,
and W Sundquist1 1 2 Univ of Utah, Salt Lake City, US; Harvard Med Sch, Boston, MA,
US; and 3Myriad Genetics Inc, Salt Lake City, UT, US
5:30 103 Role of GGA and Arf Proteins in HIV-1 Assembly and
Release
A Joshi1 , J Bonifacino2 , and Eric Freed* 1
1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US and Natl Inst
of Child Hlth and Human Devt, NIH, Bethesda, MD, US
5:45 104a Modulation of Viral Assembly and Virion Release by Vpu
John Guatelli* 1,2 , D Goff1 , and N Van Damme2 1 2 Univ of California, San Diego, US and VA Hlthcare System, San
Diego, CA, US
6:00 104bLB Identification of Host Proteins Required for HIV
Infection through a Functional Genomic Screen
Abraham Brass* 1,2,3 , D Dykxhoorn3,4 , Y Benita3 , N Yan3,4 , A Engelman5 ,
R Xavier3 , J Lieberman3,4 , and S Elledge2,3 1 2 Massachusetts Gen Hosp, Boston, US; Brigham and Women’s
Hosp, Boston, MA, US; 3Harvard Med Sch, Boston, MA, US;
4 5 Immune Disease Inst, Boston, MA, US; and Dana-Farber Cancer
Inst, Boston, MA, US
e Tuesday, 4-6 pm; Ballroom B/C
Session 32–Symposium CME
Aging and AIDS
Conveners:
Amy Justice, Yale Univ Sch of Med, New
Haven, CT, US
Michael Lederman, Case Western Reserve
Univ, Sch of Med, Cleveland, OH, US
105
Immune Exhaustion in Aging and AIDS: Parallel
Mechanisms and Possible Solutions
Rita Effros
David Geffen Sch of Med, Univ of California, Los Angeles, US
106
The Effect of Aging on Human Pharmacology
Charles Flexner
Johns Hopkins Univ, Baltimore, MD, US
107
Contributions of Age-related Morbidities
William Powderly
Univ Coll Dublin, Ireland
108
Epidemiology of HIV, including Response to ART, in
Older Populations
Bruno Ledergerber
Univ Hosp Zurich, Switzerland
Objectives: This session is directed to clinicians and researchers interested
in the immunopathogenesis of HIV infection and aging and in the clinical
management of HIV infection in older individuals. The session will describe
the effects of aging on the normal immune system and the interactions between
the effects of aging and of HIV infection on immune function.; identify
changes in drug metabolism and pharmacodynamics with age; list strategies
for overcoming the challenges in managing diseases of aging in the context of
HIV infection; and enable the participant to recognize the effect of aging on
response to treatment with ART. It is assumed that participants are familiar
with basic HIV-related immunology and management of HIV disease. At the
completion of the session, participants will be able to identify the challenges of
managing HIV infection in an aging population, the complex interrelationships
between management of HIV disease and of diseases of aging, and will
understand some of the immunologic issues that underlie changes due to aging
and their effect on HIV and its complications.
Program 17
Tuesday
February 5 Sessions